Decreased albuminuria by pravastatin in hyperlipidemic diabetics.

Keywords

Medicine, Albuminuria, Pravastatin, Hyperlipidemia, Rosuvastatin

References

• Receptor-mediated endocytosis of low-density lipoprotein by cultured human glomerular cells.Hugh C. Rayner, Terry Horsburgh, Sally L. Brown — 1990
• Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome.Kevin P.G. Harris, Mabel L. Purkerson, Jesse Yates — 1990
• Alterations in serum lipids and apolipoproteins in male Type 1 (insulin-dependent) diabetic patients with microalbuminuriaRobin P. F. Dullaart, L.D. Dikkeschei, H Doorenbos — 1989
• Blood Pressure Changes and Renal Function in Incipient and Overt Diabetic NephropathyC. E. Mogensen, Cramer Christensen — 1985
• Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus.G C Viberti, R. J. Jarrett, U. Mahmud — 1982
• Partial remission of nephrotic syndrome in patient on long-term simvastatin.Ton J. Rabelink, R. J. Hené, D.W. Erkelens — 1990
• Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes.Bo Feldt‐Rasmussen, E. R. Mathiesen, T. Deckert — 1986
• Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.C. E. Mogensen — 1984

Cited by

• Lipid disturbances in chronic renal failure--patomechanisms and treatment.Leszek Rutkowski, Michael S. Chmielewski — 2004
• Lipids, protein intake, and diabetic nephropathy.H. Gin, Vincent Rigalleau, M Aparicio — 2000
• Diurnal rhythm of cholesterol biosynthesis in experimental chronic renal failureMichael S. Chmielewski, Tomasz Niewęgłowski, Julian Świerczyński — 2001
• Pathobiochemistry of nephrotic syndrome.Vladimı́r Tesař, Tomáš Zima, Marta Kalousová — 2003
• Treatment of hyperlipidaemia in patients with non-insulin-dependent diabetes mellitus with progressive nephropathy.Ignatius K.P. Cheng, Karen S.L. Lam, Edward Janus — 1997
• Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.Akira Owada, Shin Suda, Toshihiko Hata — 2003
• Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice.Anja Mühlfeld, Min W. Spencer, Kelly L. Hudkins — 2004
• Role of lipid control in diabetic nephropathy.Hung‐Chun Chen, Jinn‐Yuh Guh, Jer‐Ming Chang — 2005
• Increased frequency of the apolipoprotein E2 allele in maintenance haemodialysis patients in TaiwanMing‐Chia Hsieh, Shiu‐Ru Lin, Chao‐Sheng Lo — 2002
• Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose.Hung‐Chun Chen, Jinn‐Yuh Guh, Shyi‐Jang Shin — 2002
• Preferential increase in the free form of atrial natriuretic peptide in adriamycin-induced nephrotic rats.Naoto Yokota, Johji Kato, Yoshitaka Yamamoto — 1991
• Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.Karin Jandeleit‐Dahm, Zemin Cao, Alison J. Cox — 1999
• Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM.Hideki Kimura, Yu Suzuki, Fumitake Gejyo — 1998
• Lipid-lnduced Glomerular InjuryCarlos Guijarro, William F. Keane — 1994
• Methods of literature review and synthesis.BE Coronado, Dengpan Bu, Andrew S. Levey — 1998
• Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.Philip Raskin, Om P. Ganda, Sherwyn Schwartz — 1995
• Microalbuminuria in Non—Insulin-Dependent Diabetes Mellitus: Implications for Renal SurvivalKevin C. Abbott — 1994
• Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients.A. Zhang, Jan Vertommen, L. Van Gaal — 1995
• Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.Takashi Nagai, Takashi Tomizawa, Katsuyuki Nakajima — 2000
• Lipids and the kidney.William F. Keane — 1994

Related papers

• Achieving lipid goals in real life: the Dutch DISCOVERY StudyA. F. E. Bots, John J.P. Kastelein, on behalf of the discovery netherlands investigators — 2005
• Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.W. Virgil Brown, Harold Bays, David Hassman — 2002
• Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind StudyR. Paoletti, Mohmed I Fahmy, Gerhard Mahla — 2001
• Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata — 2012
• Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.Ken-ichi Nezasa, Kazutaka Higaki, Tadahiko Matsumura — 2002
• Achievement of English National Service Framework lipid‐lowering goals: pooled data from recent comparative treatment trials of statins at starting dosesRichard Hobbs, Sue Southworth — 2005
• A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1).Tsutomu Yamazaki, Masahiko Kurabayashi — 2009